Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3726-3731

  Dutta, Noton K ^a   Illei, Peter B ^a   Peloquin, Charles A ^b   Pinn, Michael L ^a   Mdluli, Khisimuzi E ^c   Nuermberger, Eric L ^a,d   Grosset, Jacques H ^a   Karakousis, Petros C ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GUINEA PIG; HUMAN; LUNG; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; GUINEA PIGS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS;

EID: 84862549646     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00500-12     Document Type: Article

References (39)

1. Ahmad Z, et al. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob. Agents Chemother. 55:1527-1532.
2. Ahmad Z, et al. 2011. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J. Antimicrob. Chemother. 66:1560-1566.
3. Ahmad Z, et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
4. Ahmad Z, et al. 2010. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729-734.
5. Ahmad Z, et al. 2010. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J. Antimicrob. Chemother. 65:2172-2175.
6. Almeida D, et al. 2011. Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl. Trop. Dis. 5:e933. doi:10.1371/journal.pntd.0000933.
7. Aly S, et al. 2006. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210:298-305.
8. Benator D, et al. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360:528-534.
9. Burman WJ, Gallicano K, Peloquin C. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
10. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. 2004. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170:1124-1130.
11. Davis SL, et al. 2009. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 4:e6297. doi:10.1371/journal.pone.0006297.
12. Davis SL, et al. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy- Dglucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
13. Dorman S, et al. 2011. A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for tuberculosis trials consortium study 29. Am. J. Respir. Crit. Care Med. 183:A6413.
14. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551.
15. Gumbo T, et al. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
16. Jayaram R, et al. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
17. Karakousis PC, Williams EP, Bishai WR. 2008. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 61:323-331.
18. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. 2008. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198:275-283.
19. Lenaerts AJ, et al. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51:3338-3345.
20. Li J, Munsiff SS, Driver CR, Sackoff J. 2005. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin-or rifabutin-based regimens in New York City, 1997-2000. Clin. Infect. Dis. 41:83-91.
21. McMurray DN. 2001. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7:135-137.
22. Mor N, Simon B, Mezo N, Heifets L. 1995. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
23. Ordway DJ, et al. 2010. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother. 54:1820-1833.
24. Peloquin CA, et al. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
25. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
26. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174:2190-2201.
27. Rees RJ, Hart PD. 1961. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. 42:83-88.
28. Rosenthal IM, et al. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101.
29. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989-993.
30. Rosenthal IM, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi:10.1371/journal.pmed.0040344.
31. Roy CJ, et al. 2012. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob. Agents Chemother. 56:883-886.
32. Shang S, et al. 2011. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother. 55:124-131.
33. Strolin BM, Dostert P. 1994. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102:101-105.
34. Vandiviere HM, Loring WE, Melvin I, Willis S. 1956. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232:30-37.
35. Vernon A, Burman W, Benator D, Khan A, Bozeman L. 1999. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353:1843-1847.
36. Weiner M, et al. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197.
37. Weiner M, et al. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care. Med. 167:1341-1347.
38. Weiner M, et al. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192-4200.
39. Zhang M, et al. 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254-1261.